# Teitur Trophics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/teitur-trophics

- Industry: Biotechnology
- Headquarters: Denmark
- Website: www.teiturtrophics.com
- Total disclosed funding: $30M
- Latest round: Series A (Mar 14, 2023)
- Investors on record: 5

## About

Based in Aarhus, Denmark, and founded in 2020 by Simon Molgaard (CEO), Anders Dalby, Mathias Kaas Ollendorff, and Simon Glerup, Teitur Trophics operates as a biotechnology research company developing circular peptides for the treatment of neurodegenerative disorders, such as Huntington’s disease, Parkinson’s disease, and frontotemporal dementia. In March 2023, Teitur Trophics raised EUR 28 million in series A funding co-led by Sound Bioventures and Sunstone Life Science Ventures. 

Teitur Trophics is an operator of a medical research company that is being studied on small peptides involved in neurodegenerative diseases such as Huntington's, Alzheimer's, and Parkinson's disease. Furthermore, the firm's research focuses on receptors that are central to neural function, and by understanding the biology of the receptor, healthcare experts can modulate key mechanisms in neural function, allowing them to develop treatments that can prevent disease development through daily injections.

The company plans to use the March 2023 funding to progress its lead drug candidate, TT-P34, from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases.

## Funding rounds

- Series A, Mar 14, 2023, $30M — Industrifonden, Innovestor, Sunstone Life Science Ventures, Sound Bioventures, p53

## Investors

- Industrifonden (https://capitalatlas.ai/funds/industrifonden) — Series A
- Innovestor (https://capitalatlas.ai/funds/innovestor) — Series A
- Sunstone Life Science Ventures (https://capitalatlas.ai/funds/sunstone-life-science-ventures) — Series A
- Sound Bioventures (https://capitalatlas.ai/funds/sound-bioventures) — Series A
- p53 (https://capitalatlas.ai/funds/p53) — Series A